Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Classical hematology 1CNS 1

Conditions

Lymphoma 113Leukemia 80Precursor Cell Lymphoblastic Leukemia-Lymphoma 61Lymphoma, Non-Hodgkin 59Multiple Myeloma 56Leukemia, Myeloid, Acute 56Lymphoma, Large B-Cell, Diffuse 55Hodgkin Disease 48Myelodysplastic Syndromes 43Burkitt Lymphoma 43Lymphoma, Follicular 41Leukemia, Lymphocytic, Chronic, B-Cell 41Lymphoma, Mantle-Cell 40Breast Neoplasms 35Lymphoma, Large-Cell, Immunoblastic 34Sarcoma 27Neoplasms, Plasma Cell 27Central Nervous System Neoplasms 25Lymphoma, B-Cell, Marginal Zone 24Dendritic Cell Sarcoma, Interdigitating 19Recurrence 18Leukemia, Myelogenous, Chronic, BCR-ABL Positive 18Ovarian Neoplasms 16Neuroblastoma 16Myeloproliferative Disorders 16Leukemia, Myeloid, Chronic-Phase 16Leukemia, Myeloid, Accelerated Phase 15Congenital Abnormalities 15Neutropenia 13Lung Neoplasms 13

Interventions

Amifostine 10Cisplatin 8Radiotherapy 7Etoposide 6Cyclophosphamide 4Carboplatin 4Paclitaxel 3pegfilgrastim 2camrelizumab 2apatinib 2Mitoxantrone 2Filgrastim 2Drug Therapy 2Cytarabine 2sodium thiosulfate 1sargramostim 1pazopanib 1icotinib 1glucarpidase 1etoposide phosphate 1denileukin diftitox 1Vitamin E 1Triptorelin Pamoate 1Tocopherols 1Thiotepa 1Tegafur 1Taxes 1Surgical Procedures, Operative 1Silymarin 1Rituximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Drug-Related Side Effects and Adverse Reactions × Filgrastim × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT00004132 2013-06-26

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

National Cancer Institute (NCI)

Phase 2 Completed
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blast Crisis, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Radiation Injuries, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡